Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ixekizumab

ixekizumab

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ixekizumab

28 trials tracked of ixekizumab: 18 in phase 3 or 4 and 14 with published results. The most-cited published study has 122 citations.

28Trials tracked
18Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 4 Phase 3 14 Phase 2 5 Phase 1 5
  1. Phase 4 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 122 cited
  2. Phase 3 A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis Completed · 50 cited
  3. Phase 3 Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Completed · 46 cited
  4. Phase 4 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis Completed · 44 cited
  5. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment Completed · 43 cited
  6. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 40 cited
Show 22 more trials
  1. Phase 4 A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed · 33 cited
  2. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Completed · 27 cited
  3. Phase 3 A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Completed · 21 cited
  4. Phase 3 A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Completed · 17 cited
  5. Phase 3 A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Completed · 8 cited
  6. Phase 3 A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis Completed · 8 cited
  7. Phase 3 A Study of Ixekizumab in Participants With Active Psoriatic Arthritis Completed · 8 cited
  8. Phase 3 A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis Completed · 5 cited
  9. Phase 4 A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India Completed
  10. Phase 3 A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis Completed
  11. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Completed
  12. Phase 3 A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Completed
  13. Phase 2 Targeting IL-17A for Treatment-Resistant Depression Completed
  14. Phase 2 Ixekizumab in the Treatment of Bullous Pemphigoid Completed
  15. Phase 2 A Study in Participants With Moderate to Severe Psoriasis Completed
  16. Phase 2 Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP) Completed
  17. Phase 2 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed
  18. Phase 1 A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants Completed
  19. Phase 1 A Study of Two Formulations of Ixekizumab in Healthy Participants Completed
  20. Phase 1 A Study of Ixekizumab in Participants With Plaque Psoriasis Completed
  21. Phase 1 A Study of Ixekizumab in Healthy Participants Completed
  22. Phase 1 A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
TNF-alpha inhibitors are the most frequent biological agents associated with de novo vitiligo development
Allergy & Immunology Sys. Review
TNF-alpha inhibitors are the most frequent biological agents associated with de novo vitiligo development Biological Therapies Linked to New Vitiligo Cases in Patients
This scoping review of 39 patients identifies a link between biological therapies and de novo vitiligo, most frequently involving TNF-alpha …
Some patients using biological therapies for inflammatory conditions may develop new cases of vitiligo, often appearing within months of sta…
Frontiers Oct 6, 2026
Ixekizumab combined with tirzepatide improves disease activity and weight in patients with Psoriatic Arthritis
Dermatology RCT
Ixekizumab combined with tirzepatide improves disease activity and weight in patients with Psoriatic Arthritis Trial shows combined treatment improves psoriasis and weight management
Researchers evaluated the combination of ixekizumab and tirzepatide in adults with active Psoriatic Arthritis and overweight or obesity. The…
A new combination therapy showed significant improvements in joint health and weight loss for adults living with psoriatic arthritis and obe…
Oct 1, 2026
Ixekizumab Q2W shows highest P-score among IL-17 inhibitors for active psoriatic arthritis
Allergy & Immunology Meta-analysis
Ixekizumab Q2W shows highest P-score among IL-17 inhibitors for active psoriatic arthritis New data shows IL-17 inhibitors work for psoriatic arthritis
This network meta-analysis of IL-17 pathway inhibitors in adults with active psoriatic arthritis found all active treatments superior to pla…
Several types of IL-17 pathway inhibitors show promise in treating joint pain and skin issues for people with active psoriatic arthritis.
Frontiers Aug 13, 2026
IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis
Dermatology Meta-analysis
IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis Biologics Show Different Success Rates for Scalp and Nail Psoriasis
This network meta-analysis of 5,946 patients evaluated IL-17/IL-23 axis biologics for difficult-to-treat psoriasis sites. The analysis found…
Different biologics show varying success rates for clearing psoriasis on the scalp, nails, and palms based on a large network analysis.
Frontiers Jul 23, 2026
Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis
Dermatology RCT
Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis New drug ixekizumab shows promise for children with arthritis
This multicentre, open-label, phase 3 study evaluated ixekizumab in 101 children with enthesitis-related arthritis or juvenile psoriatic art…
A phase 3 study found ixekizumab helped many children with arthritis meet response criteria at week 16, with mostly mild side effects report…
May 1, 2026
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
Dermatology Meta-analysis
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis Biologic treatments help children with moderate to severe psoriasis, analysis finds
A network meta-analysis of randomized controlled trials including 1,016 pediatric psoriasis patients found all biologic therapies significan…
Biologic medicines help children with moderate to severe psoriasis achieve clear skin and better quality of life, analysis finds.
Apr 8, 2026